1. Home
  2. ALLO vs NREF Comparison

ALLO vs NREF Comparison

Compare ALLO & NREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • NREF
  • Stock Information
  • Founded
  • ALLO 2017
  • NREF 2019
  • Country
  • ALLO United States
  • NREF United States
  • Employees
  • ALLO N/A
  • NREF N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • NREF Real Estate Investment Trusts
  • Sector
  • ALLO Health Care
  • NREF Real Estate
  • Exchange
  • ALLO Nasdaq
  • NREF Nasdaq
  • Market Cap
  • ALLO 277.8M
  • NREF 242.2M
  • IPO Year
  • ALLO 2018
  • NREF 2020
  • Fundamental
  • Price
  • ALLO $1.40
  • NREF $15.80
  • Analyst Decision
  • ALLO Strong Buy
  • NREF Hold
  • Analyst Count
  • ALLO 9
  • NREF 3
  • Target Price
  • ALLO $8.44
  • NREF $14.50
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • NREF 38.3K
  • Earning Date
  • ALLO 08-06-2025
  • NREF 07-31-2025
  • Dividend Yield
  • ALLO N/A
  • NREF 12.49%
  • EPS Growth
  • ALLO N/A
  • NREF N/A
  • EPS
  • ALLO N/A
  • NREF 2.59
  • Revenue
  • ALLO N/A
  • NREF $110,996,000.00
  • Revenue This Year
  • ALLO N/A
  • NREF $25.18
  • Revenue Next Year
  • ALLO N/A
  • NREF $3.65
  • P/E Ratio
  • ALLO N/A
  • NREF $6.19
  • Revenue Growth
  • ALLO N/A
  • NREF 370.78
  • 52 Week Low
  • ALLO $0.86
  • NREF $12.14
  • 52 Week High
  • ALLO $3.78
  • NREF $18.09
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 56.45
  • NREF 66.52
  • Support Level
  • ALLO $1.27
  • NREF $14.51
  • Resistance Level
  • ALLO $1.51
  • NREF $15.21
  • Average True Range (ATR)
  • ALLO 0.11
  • NREF 0.33
  • MACD
  • ALLO 0.04
  • NREF 0.08
  • Stochastic Oscillator
  • ALLO 77.55
  • NREF 82.89

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

Share on Social Networks: